BlackRock’s Telomir Pharmaceuticals TELO Stock Holding History

BlackRock’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$359K	Sell	280,472 -8,726	-3%	-$11.4K	﹤0.01%	4667
2026 Q1	$376K	Buy	289,198 +3,744	+1%	+$4.78K	﹤0.01%	4599
2025 Q4	$380K	Sell	285,454 -5,979	-2%	-$8.63K	﹤0.01%	4555
2025 Q3	$405K	Sell	291,433 -78,643	-21%	-$119K	﹤0.01%	4511
2025 Q2	$463K	Sell	370,076 -830,485	-69%	-$1.92M	﹤0.01%	4464
2025 Q1	$3.88M	Buy	1,200,561 +143,586	+14%	+$628K	﹤0.01%	3744
2024 Q4	$4.35M	Buy	1,056,975 +690,097	+188%	+$3.25M	﹤0.01%	3780
2024 Q3	$2.36M	Buy	366,878 +278,979	+317%	+$1.36M	﹤0.01%	3950
2024 Q2	$423K	Buy	+87,899	New	+$548K	﹤0.01%	4386

Other funds holding TELO

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

WIA

World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

BlackRock's TELO Position: Q2 2026 in Review

BlackRock reduced its Telomir Pharmaceuticals (TELO) stake by 3% in Q2 2026, selling an estimated $11.4K and leaving 280,472 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #4667.

BlackRock first reported a position in TELO in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.35M in Q4 2024. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

BlackRock held 280,472 shares of Telomir Pharmaceuticals worth $359K as of Q2 2026.
BlackRock sold 8,726 Telomir Pharmaceuticals shares in Q2 2026, an estimated $11.4K.
Telomir Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4667 holding.
BlackRock first reported a position in Telomir Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
BlackRock's Telomir Pharmaceuticals position peaked at $4.35M in Q4 2024.
33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.